Patent intelligence · US
US 10322129
Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same
Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same
Patent details — US 10322129
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 18, 2019
- Expiration
- Jun 13, 2039
- Applicant
- O.D. Ocular Discovery Ltd.
- Claims
- 18
- CPC classes
- A61K, A61K31/519, A61K9/0048, A61P
Quick answer
US 10322129 (Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same) is held by O.D. Ocular Discovery Ltd.. Status: granted. Granted Jun 18, 2019. Expires Jun 13, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- O.D. Ocular Discovery Ltd.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/519, A61K9/0048, A61P, A61P27/12, A61P35/00
More from O.D. Ocular Discovery Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 10322129?
US 10322129 (Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions and methods for producing same) is held by O.D. Ocular Discovery Ltd.. Status: granted. Granted Jun 18, 2019. Expires Jun 13, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10322129?
O.D. Ocular Discovery Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 10322129 expire?
Our index shows an expiration date of Jun 13, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.